Standout Papers

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and t... 1997 2026 2006 2016 501
  1. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. (1997)
    Franco M. Muggia, John D. Hainsworth et al. Journal of Clinical Oncology

Immediate Impact

3 by Nobel laureates 6 from Science/Nature 63 standout
Sub-graph 1 of 22

Citing Papers

Pan-cancer whole-genome comparison of primary and metastatic solid tumours
2023 StandoutNature
Self-Healing Injectable Hydrogels for Tissue Regeneration
2022 Standout
2 intermediate papers

Works of Matthew Tan being referenced

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
1997 Standout
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
1997

Author Peers

Author Last Decade Papers Cites
Matthew Tan 205 329 552 253 9 1.0k
W ten Bokkel Huinink 146 411 448 543 22 1.2k
W W ten Bokkel Huinink 164 594 408 551 20 1.2k
K. Buser 110 317 406 276 17 862
I Fryatt 309 257 436 448 20 1.0k
Els O. Witteveen 155 129 530 195 23 1.1k
E. Kutarska 92 173 430 280 17 921
T. Hakes 147 316 872 396 18 1.4k
N Onetto 91 117 646 139 21 936
F. Raja 110 225 482 761 10 1.1k
Catharina M. Kuiper 304 295 931 87 24 1.3k

All Works

Loading papers...

Rankless by CCL
2026